At a glance
- Originator TALENT Biotech
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor agonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Graft-versus-host disease
Highest Development Phases
- Phase II Graft-versus-host disease
Most Recent Events
- 01 Jun 2021 Claritas Pharmaceuticals enteres into a Debt Forgiveness Agreement with the former shareholders of Talent Biotech to transfer all assets related to Cannabidiol for the prevention and treatment of Graft versus host disease
- 15 Mar 2021 Phase II trial is ongoing for Graft-versus-host disease (Prevention) in Israel and Australia (NCT03840512) (ACTRN12619000623190)
- 26 Feb 2021 Kalytera Therapeutics is now called Claritas Pharmaceuticals